1. Introduction {#sec1-medicina-55-00425}
===============

Cancer is one of the main public health problem worldwide with about 18.1 million new cancer cases and 9.6 million cancer deaths in 2018 \[[@B1-medicina-55-00425]\]. The precise mechanisms of cancer initiation and progression has remained largely unknown \[[@B2-medicina-55-00425]\]. Mounting evidence has suggested that genetic predisposition plays a significant role in the risk of individual cancer development \[[@B3-medicina-55-00425],[@B4-medicina-55-00425]\].

Autophagy, an evolutionarily conserved process, is important for survival, differentiation, development, and homeostasis through degrading damaged organelles and long-lived proteins \[[@B5-medicina-55-00425],[@B6-medicina-55-00425],[@B7-medicina-55-00425],[@B8-medicina-55-00425]\]. Autophagy is a tightly regulated mechanism, regulated by several autophagy related genes (ATGs), and is classified into three subgroups, including macroautophagy (hereafter autophagy), microautophagy, and chaperon-mediated autophagy \[[@B9-medicina-55-00425],[@B10-medicina-55-00425],[@B11-medicina-55-00425],[@B12-medicina-55-00425],[@B13-medicina-55-00425]\]. It has been documented that autophagy is involved in multiple diseases, including cancers, infectious diseases, fibrotic diseases, neurodegeneration and aging \[[@B14-medicina-55-00425],[@B15-medicina-55-00425],[@B16-medicina-55-00425],[@B17-medicina-55-00425],[@B18-medicina-55-00425],[@B19-medicina-55-00425],[@B20-medicina-55-00425],[@B21-medicina-55-00425]\]. During cancer development, autophagy is considered a double edge sword because it can support or prevent cancer development through different mechanisms, including apoptotic cell death, chemo-resistance, tumorigenesis and metastasis \[[@B16-medicina-55-00425],[@B22-medicina-55-00425],[@B23-medicina-55-00425],[@B24-medicina-55-00425],[@B25-medicina-55-00425],[@B26-medicina-55-00425]\].

The autophagy-related 16-like 1 gene (*ATG16L1*) is located on the long arm of chromosome 2 (2q37.1) \[[@B27-medicina-55-00425]\]. It encodes ATG16L1, which is a component of a large protein complex essential for autophagy \[[@B28-medicina-55-00425]\]. ATG16L1 plays an essential role in regulation of LC3 lipidation, and formation and insertion of lipidated LC3 into double membrane autophagosomes \[[@B29-medicina-55-00425]\]. ATG16L1 is also involved in regulation of carcinogenesis in many cancers. As an example, it has been reported that the Thr300Ala variant of ATG16L1 is associated with a decrease in brain metastasis of non-small cell lung cancer \[[@B30-medicina-55-00425]\]. The nonsynonymous rs2241880 (Thr300Ala) polymorphism in the *ATG16L1* gene is situated on coding exon 9.

Several studies that have investigated the relationship between the rs2241880 (Thr300Ala) polymorphism in *ATG16L1* and several cancers among different ethnic populations have had conflicting outcomes \[[@B31-medicina-55-00425],[@B32-medicina-55-00425],[@B33-medicina-55-00425],[@B34-medicina-55-00425],[@B35-medicina-55-00425],[@B36-medicina-55-00425],[@B37-medicina-55-00425],[@B38-medicina-55-00425],[@B39-medicina-55-00425]\]. Therefore, for the first time, we aimed to conduct a meta-analysis of all available studies published to date to examine the impact of the *ATG16L1* rs2241880 polymorphism on cancer susceptibility.

2. Methods {#sec2-medicina-55-00425}
==========

2.1. Literature Search {#sec2dot1-medicina-55-00425}
----------------------

In order to identify eligible articles, we comprehensively searched the Web of Science, PubMed, and Scopus databases, up to April 2019, for the relationship between the *ATG16L1* rs2241880 polymorphism and susceptibility to cancer. The search terms used were "ATG16L1 or autophagy related 16 like 1" and "cancer or malignant or tumor" and "polymorphism or variant or rs2241880 or T300A or +898A \> G" or Thr300Ala. The selection process of eligible studies is shown in [Figure 1](#medicina-55-00425-f001){ref-type="fig"}. Studies consistent with the following criteria were included in the meta-analysis: case-control studies that focused on the correlation between the *ATG16L1* polymorphism and risk of cancer, with sufficient information for estimation of the odds ratios (ORs) and their 95% confidence intervals. Studies were excluded from consideration if not correlated to *ATG16L1* polymorphism and cancer risk; conference papers, reviews, meta-analyses; and studies without detailed genotyping data.

2.2. Data Extraction {#sec2dot2-medicina-55-00425}
--------------------

Two authors screened and extracted the data from eligible studies independently. Any disagreements were discussed with the third author. The following data were extracted from each study including the first author's name, year of publication, country, ethnicity, type of cancer, source of control, genotyping methods, sample size, as well as genotype and allelic frequencies of the cases and controls.

2.3. Statistical Analysis {#sec2dot3-medicina-55-00425}
-------------------------

The Hardy--Weinberg equilibrium (HWE) of control genotypes was inspected using a χ2 test. We used pooled odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association of the *ATG16L1* polymorphism with cancer risk in five genetic models. The significance of the pooled OR was determined by the *z*-test, and a *p* \< 0.05 was considered statistically significant.

Heterogeneity among the studies was assessed by using the Q statistic and the I^2^ statistic. *p* \< 0.10 was considered statistically significant. The random effects model was applied if heterogeneity was observed among studies; otherwise, the fixed effects model was used.

Publication bias was inspected visually by a funnel plot and an asymmetric plot suggested a possible publication bias. Funnel plot asymmetry was measured further using the Egger and Begg tests. A *p* value \< 0.05 was considered significant publication bias.

Sensitivity analysis was conducted to evaluate whether the findings were affected significantly by a single study by neglecting each study in turn to determine the effect on the pooled analysis. Statistical analyses were achieved using the STATA 14.1 software and Review Manager 5.3.

3. Results {#sec3-medicina-55-00425}
==========

3.1. Study Characteristics {#sec3dot1-medicina-55-00425}
--------------------------

Through the literature search and selection in accordance with the inclusion criteria, nine articles, including 12 case-control studies, comprising 2254 cases and 4974 controls, were ultimately included in the quantitative analysis ([Table 1](#medicina-55-00425-t001){ref-type="table"}). The genotype distributions of the *ATG16L1* rs2241880 polymorphism in all subjects are shown in [Table 1](#medicina-55-00425-t001){ref-type="table"}. The genotype distributions in the controls of the 12 studies were fitted into the HWE, except for two studies \[[@B31-medicina-55-00425],[@B35-medicina-55-00425]\].

3.2. Main Analysis Results {#sec3dot2-medicina-55-00425}
--------------------------

As shown in [Figure 2](#medicina-55-00425-f002){ref-type="fig"} and [Table 2](#medicina-55-00425-t002){ref-type="table"}, the findings did not support a correlation between the *ATG16L1* rs2241880 polymorphism and cancer risk. Overall, no significant associations were found for AG vs. AA (OR = 0.94, 95% CI = 0.74--1.20, *p* = 0.63, [Figure 2](#medicina-55-00425-f002){ref-type="fig"}A), CG vs. AA (OR = 0.93, 95% CI = 0.72--1.20, *p* = 0.58, [Figure 2](#medicina-55-00425-f002){ref-type="fig"}B), AG + GG vs. AA (OR = 0.94, 95% CI = 0.94--1.19, *p* = 0.60, [Figure 2](#medicina-55-00425-f002){ref-type="fig"}C), GG vs. AG + AA (OR = 0.98, 95% CI = 0.81--1.18, *p* = 0.80, [Figure 2](#medicina-55-00425-f002){ref-type="fig"}D), and G vs. A (OR = 0.97, 95%CI = 0.84--1.12, *p* = 0.65, [Figure 2](#medicina-55-00425-f002){ref-type="fig"}E).

3.3. Subgroup Analysis {#sec3dot3-medicina-55-00425}
----------------------

Stratified analysis was achieved by cancer types and ethnicity ([Table 3](#medicina-55-00425-t003){ref-type="table"}). The stratified analysis revealed no association between the *ATG16L1* rs2241880 variant and either cancer types or ethnicities.

3.4. Heterogeneity and Publication Bias {#sec3dot4-medicina-55-00425}
---------------------------------------

There were significant heterogeneities in all genetic models examined except for the recessive model ([Table 2](#medicina-55-00425-t002){ref-type="table"}). Begg's funnel plot and Egger's linear regression test revealed no apparent publication bias in our overall analysis in any genetic models ([Table 2](#medicina-55-00425-t002){ref-type="table"} and [Figure 3](#medicina-55-00425-f003){ref-type="fig"}).

3.5. Sensitivity Analysis {#sec3dot5-medicina-55-00425}
-------------------------

A sensitivity analysis was done to inspect the impact of an individual study on the pooled ORs. The results indicated that the pooled ORs were not significantly affected by a single study, suggesting that the pooled results are reliable ([Figure 4](#medicina-55-00425-f004){ref-type="fig"}).

4. Discussion {#sec4-medicina-55-00425}
=============

It has been shown that the nonsynonymous rs2241880 (Thr300Ala) polymorphism of the *ATG16L1* gene affects the autophagy process \[[@B40-medicina-55-00425]\] and also modulates the production of interleukin-1 beta (IL-1β) in human cells \[[@B41-medicina-55-00425]\]. The exact effect of the *ATG16L1* rs2241880 polymorphism on the pathogenesis of cancer is not fully understood. Several studies investigated the impact of the *ATG16L1* rs2241880 polymorphism on susceptibility to cancer. Al-Ali et al. \[[@B39-medicina-55-00425]\] reported that the rs2241880 variant significantly decreased the risk of lung cancer in a Spanish population. Budak Diler et al. \[[@B31-medicina-55-00425]\] showed that the rs2241880 variant was not associated with the risk of prostate cancer or bladder cancer in a Turkish population. Burada et al. \[[@B32-medicina-55-00425]\] found that the rs2241880 polymorphism was associated with protection against gastric cancer in a Romanian population. Cao et al. \[[@B38-medicina-55-00425]\] found no significant association between the rs2241880 variant and colorectal cancer in a Chinese population. Castano-Rodriguez \[[@B33-medicina-55-00425]\] reported that the rs2241880 polymorphism significantly increased the risk of gastric cancer in a Singaporean population. Fernandez-Mateos et al. \[[@B34-medicina-55-00425]\] showed that the rs2241880 variant significantly increased the risk of oral cavity cancer but the variant was not associated with the risk of laryngeal cancer or pharyneal cancer in a Spanish population. Huijbers et al. \[[@B35-medicina-55-00425]\] revealed that the rs2241880 variant was associated with protection against thyroid cancer in a Netherlander population. Nicoli et al. \[[@B36-medicina-55-00425]\] showed that rs2241880 variant significantly increased the risk of colorectal cancer in a Romanian population. Wisetsathorn et al. \[[@B37-medicina-55-00425]\] observed that the rs2241880 variant significantly increased the risk of hepatocellular carcinoma in a Thai population. Figlioli et al. \[[@B42-medicina-55-00425]\] proposed that the *ATG16L1* rs2241880 variant significantly decreased the risk of thyroid cancer. Due to insufficient data this study was excluded from the meta-analysis.

To the best of our knowledge, this is the first meta-analysis that aimed to investigate the possible association between the *ATG16L1* rs2241880 gene polymorphism and overall cancer susceptibility. Our findings showed no significant association between the rs2241880 polymorphism of the *ATG16L1* gene and cancer susceptibility in any genetic models. The results of this meta-analysis are not consistent with some previous studies \[[@B32-medicina-55-00425],[@B33-medicina-55-00425],[@B34-medicina-55-00425],[@B36-medicina-55-00425],[@B37-medicina-55-00425]\]. The discrepancy between studies may be attributed to small sample sizes, type of cancer and different genetic backgrounds among the diverse ethnicities of the above-mentioned studies.

How the rs2241880 (Thr300Ala) polymorphism alters the biology of ATG16L1 is not yet known. Yuan et al. \[[@B43-medicina-55-00425]\] showed that the *ATG16L1* rs2241880 polymorphism was significantly associated with survival in lung adenocarcinoma patients.

In spite of the heterogeneity across studies, no evidence of publication bias was detected by either Begg's or Egger's tests. In addition, the sensitivity analysis did not significantly alter the overall results for all genetic models, which implies stability and reliability for our findings.

This meta-analysis has some limitations that should be taken into account. First, only published articles in English were included in the pooled analysis because data in other languages and data from other ongoing studies were not available. Second, heterogeneity was observed among the studies, which have distorted the conclusion. The heterogeneity among studies may be due to differences in cancer types and ethnicities. Third, we calculated crude ORs, which were unadjusted estimations. Fourth, due to the lack of raw data, we were unable to perform gene--environment interactions. Finally, the number of individual studies for each cancer type was inadequate for stratified analysis. Our findings should therefore be interpreted with caution.

5. Conclusions {#sec5-medicina-55-00425}
==============

In conclusion, the current study is the first meta-analysis to evaluate the association between the *ATG16L1* rs2241880 polymorphism and the risk of cancer. Our results did not support an association between the *ATG16L1* rs2241880 polymorphism and cancer risk. Larger well-designed studies are needed to elucidate the exact role of the *ATG16L1* rs2241880 polymorphism on cancer risk.
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![Flow chart shows the detailed study selection process of this meta-analysis.](medicina-55-00425-g001){#medicina-55-00425-f001}

###### 

The forest plots for the association between the *ATG16L1* rs2241880 polymorphism and cancer risk for AG vs. AA (**A**), GG vs. AA (**B**), AG + GG vs. AA (**C**), GG vs. AG + AA (**D**), and G vs. A (**E**).
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![Begg's funnel plot on publication bias for association between the *ATG16L1* rs2241880 polymorphism and cancer risk for AG vs. AA (**A**), GG vs. AA (**B**), AG + GG vs. AA (**C**), GG vs. AG + AA (**D**), and G vs. A (**E**).](medicina-55-00425-g003){#medicina-55-00425-f003}

![Sensitivity analyses for studies on *ATG16L1* rs2241880 polymorphism and cancer risk for AG vs. AA (**A**), GG vs. AA (**B**), AG + GG vs. AA (**C**), GG vs. AG + AA (**D**), and G vs. A (**E**).](medicina-55-00425-g004){#medicina-55-00425-f004}

medicina-55-00425-t001_Table 1

###### 

Characteristics of all studies included in the meta-analysis.

  First Author                                            Year   Country       Ethnicity   Cancer Type          Source of Control   Genotyping Method   Case/Control   Cases   Controls   HWE (P)                                                 
  ------------------------------------------------------- ------ ------------- ----------- -------------------- ------------------- ------------------- -------------- ------- ---------- --------- ------ ----- ----- ------ ----- ------ ------ -------
  Al-Ali et al. \[[@B39-medicina-55-00425]\]              2017   Spain         Caucasian   Lung cancer          PB                  TaqMan              165/144        38      95         32        171    159   35    67     42    137    151    0.420
  Budak Diler et al. \[[@B31-medicina-55-00425]\]         2018   Turkey        Asian       Prostate cancer      PB                  PCR-RFLP            62/113         22      21         19        65     59    30    48     35    108    118    0.114
  Budak Diler et al. \[[@B31-medicina-55-00425]\]         2018   Turkey        Asian       Bladder cancer       PB                  PCR-RFLP            69/156         24      28         17        76     62    50    62     44    162    150    0.011
  Burada et al. \[[@B32-medicina-55-00425]\]              2016   Romania       Caucasian   Gastric cancer       HB                  TaqMan              108/242        34      46         28        114    102   47    122    73    216    268    0.755
  Cao et al. \[[@B38-medicina-55-00425]\]                 2016   China         Asian       Colorectal cancer    HB                  Illumina            964/891        384     463        117       1231   697   377   399    115   1153   629    0.558
  Castano-Rodriguez et al. \[[@B33-medicina-55-00425]\]   2015   Singapore     Asian       Gastric cancer       HB                  MassARRAY iPLEX     86/217         28      49         9         105    67    109   81     27    299    135    0.057
  Fernandez-Mateos et al. \[[@B34-medicina-55-00425]\]    2017   Spain         Caucasian   Larynx cancer        HB                  TaqMan              213/253        58      108        47        224    202   72    130    51    274    232    0.580
  Fernandez-Mateos et al. \[[@B34-medicina-55-00425]\]    2017   Spain         Caucasian   Pharynx cancer       HB                  TaqMan              165/253        44      81         40        169    161   72    130    51    274    232    0.580
  Fernandez-Mateos et al. \[[@B34-medicina-55-00425]\]    2017   Spain         Caucasian   Oral cavity cancer   HB                  TaqMan              72/253         18      31         23        67     77    72    130    51    274    232    0.580
  Huijbers et al. \[[@B35-medicina-55-00425]\]            2012   Netherlands   Caucasian   Thyroid cancer       PB                  \-                  139/1964       38      69         32        145    133   378   1029   557   1785   2143   0.012
  Nicoli et al. \[[@B36-medicina-55-00425]\]              2014   Romania       Caucasian   Colorectal cancer    HB                  TaqMan              109/357        14      52         43        80     138   70    179    108   319    395    0.787
  Wisetsathorn et al. \[[@B37-medicina-55-00425]\]        2017   Thailand      Asian       HCC                  HB                  PCR-RFLP            102/131        65      33         4         163    41    55    65     11    175    87     0.175

medicina-55-00425-t002_Table 2

###### 

The pooled ORs and 95% CIs for the association between *ATG16L1* rs2241880 polymorphisms and cancer susceptibility.

  Genetic Model    Association Test    Heterogeneity Test   Test of Publication Bias                                
  ---------------- ------------------- -------------------- -------------------------- ------- ---- ------- ------- -------
  AG vs. AA        0.94 (0.74--1.20)   0.48                 0.63                       33.17   67   0.000   0.425   0.411
  GG vs. AA        0.93 (0.72--1.20)   0.55                 0.58                       22.30   51   0.022   0.726   0.891
  AG + GG vs. AA   0.94 (0.74--1.19)   0.53                 0.60                       35.55   69   0.000   0.523   0.891
  GG vs. AG + AA   0.98 (0.81--1.18)   0.25                 0.80                       17.76   38   0.087   0.677   0.493
  AG vs. GG + AA   0.97 (0.80--1.17)   0.36                 0.72                       27.55   60   0.004   0.321   0.411
  G vs. A          0.97 (0.84--1.12)   0.45                 0.65                       31.99   66   0.001   0.567   0.583

medicina-55-00425-t003_Table 3

###### 

Stratified analysis of the *ATG16L1*, rs2241880 polymorphism on cancer susceptibility.

  Type of Cancer                          N   AG vs. AA           GG vs. AA   AG + GG vs. AA      GG vs. AG + AA   AG vs. GG + AA      G vs. A                                                                             
  --------------------------------------- --- ------------------- ----------- ------------------- ---------------- ------------------- --------- ------------------- ------ ------------------- ------ ------------------- ------
  Cancer type                                                                                                                                                                                                              
  Digestive tract system                  4   1.19 (0.71--1.98)   0.51        1.05 (0.65--1.70)   0.85             1.17 (0.72--1.92)   0.52      1.00 (0.81--1.22)   0.98   1.12 (0.78--1.62)   0.54   1.09 90.84--1.41)   0.51
  Colorectal cancer                       2   1.16 (0.96--1.40)   0.12        1.32 (0.68--2.55)   0.42             1.21 (0.87--1.67)   0.25      1.06 (0.84--1.34)   0.62   1.10 (0.93--1.30)   0.26   1.16 (0.88--1.54)   0.30
  Gastric cancer                          2   1.11 (0.25--4.86)   0.89        0.79 (0.33--1.88)   0.59             1.05 (0.27--4.06)   0.95      0.81 (0.53--1.25)   0.35   1.27 (0.43--3.77)   0.67   1.00 (0.52--1.94)   0.99
  Head and neck squamous cell carcinoma   3   1.01 (0.76--1.34)   0.94        1.32 (0.94--1.85)   0.11             1.10 (0.84--1.44)   0.49      1.31 (0.99--1.74)   0.06   0.89 (0.70--1.13)   0.35   1.14 (0.97--1.35)   0.12
  Ethnicity                                                                                                                                                                                                                
  Caucasian                               7   0.92 (0.76--1.11)   0.37        1.00 (0.68--1.47)   0.98             0.95 (0.72--1.25)   0.70      1.04 (0.78--1.39)   0.77   0.94 (0.80--1.09)   0.40   1.00 (0.83--1.21)   0.99
  Asian                                   5   0.94 (0.57--1.57)   0.81        0.92 (0.72--1.17)   0.47             0.91 (0.57--1.46)   0.69      0.89 (0.71--1.11)   0.30   1.00 (0.65--1.54)   0.99   0.91 (0.69--1.20)   0.50
